Bill Meagher

Bill Meagher's focus with The Deal is on small and microcap equity finance, healthcare and biotechnology, PIPEs, and companies going public. His work has appeared in newspapers and magazines throughout California as well as on PBS, “60 Minutes,” ABC News and CNBC. Meagher has also written video scripts and produced national events for a non-profit educational organization and ghost written two books.

Recent Articles By The Author

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday

FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.

Mylan CEO Defends Company From Proxy Critics

Mylan CEO Defends Company From Proxy Critics

As a June 22 shareholder reckoning approaches, CEO Bresch insisted that ISS and other critics have mischaracterized the nature of the pay package of Mylan's chairman.

Medical Device Company Sells $13M in Stock at a Discount of More than 50%

Medical Device Company Sells $13M in Stock at a Discount of More than 50%

MRI Interventions has plans to jump from over-the-counter trading to a senior exchange, and just raised $13 million to fuel the company's growth.

19 Dead, More Than 50 Seriously Injured in Possible Terror Bombing at U.K. Concert

19 Dead, More Than 50 Seriously Injured in Possible Terror Bombing at U.K. Concert

Officials say incident is being treated as a suicide bombing; witnesses say explosion so powerful 'the ground shook.'